- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03523481
NHF in Acute Hypercapnic Acute Exacerbation of COPD
June 21, 2018 updated by: Jens Bräunlich, MD
Patients with AECOPD and NIV failure and in absence will be treated with NHF device.
Inclusion criteria are pH < 7,38 and pCO2 > 45 mm Hg.
Patients were treated if pH >7,38 or refusal of therapy.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
38
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leipzig, Germany
- University of Leipzig
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with AECOPD and failure of NIV therapy
Description
Inclusion Criteria:
- pH < 7,38
- hypercapnic AECOPD
Exclusion Criteria:
- Need of intubation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
NHF use
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pH
Time Frame: up to 24 hours
|
Increase in pH
|
up to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCO2
Time Frame: up to 24 hours
|
Decrease in pCO2
|
up to 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2018
Primary Completion (Actual)
May 30, 2018
Study Completion (Actual)
May 30, 2018
Study Registration Dates
First Submitted
April 2, 2018
First Submitted That Met QC Criteria
May 1, 2018
First Posted (Actual)
May 14, 2018
Study Record Updates
Last Update Posted (Actual)
June 25, 2018
Last Update Submitted That Met QC Criteria
June 21, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety of NHF in Acute Hypercapnic AECOPD
-
Charles BerdeCompletedSafety of Neosaxitoxin in Healthy VolunteersUnited States
-
Belfast Health and Social Care TrustRecruitingAcute Hypercapnic Respiratory Failure | Acute Exacerbation of COPDUnited Kingdom
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in ElderlyUnited States
-
Ataturk UniversityUnknownThis Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.Turkey
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
-
The People's Hospital of GaozhouRecruitingExploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution in Improving Nutritional Status of Maintenance Peritoneal Dialysis PatientsChina
-
Fang WuXiangya Hospital of Central South University; Hunan Cancer Hospital; The Third...RecruitingThe Efficacy and Safety of SBRT in MPLCChina
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
-
Chinese PLA General HospitalUnknownEvaluate the Safety and Effectiveness of Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Donor SitesChina